Male Reproductive Health Including Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$727,685.00
Summary
My previous contributions to Andrology and Endocrinology of the Testis provide me with a significant breadth of expertise and a sustained record of contribution to Men’s Reproductive Health. My recent research effort has focused on Urology and prostate cancer. Through my prostate cancer research program, my overall strategy is to understand the biology of the prostate gland to enable the development of new therapies for prostate cancer, as well as for BPH (enlargement of the prostate) and prosta ....My previous contributions to Andrology and Endocrinology of the Testis provide me with a significant breadth of expertise and a sustained record of contribution to Men’s Reproductive Health. My recent research effort has focused on Urology and prostate cancer. Through my prostate cancer research program, my overall strategy is to understand the biology of the prostate gland to enable the development of new therapies for prostate cancer, as well as for BPH (enlargement of the prostate) and prostatitis (inflammation of the prostate gland).Read moreRead less
Novel Endocrine Approaches To Diagnosis & Treatment Of Men With Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$926,980.00
Summary
Most men are diagnosed with localised prostate cancer, others have advanced disease. Vision: Identify how tumours are insignificant vs aggressive (Aim 1.1 & 1.2). Predict which tumours will progress to incurable disease (Aim 1.3) and how to target them (Aim 1.4). Discover how each patient tumour is different (Aim 2.1) and pre-clinically test new therapies (Aim 2.2). Outcomes: practice changing discoveries that identify novel therapeutic targets & biomarkers improving diagnosis and treatment.
Genetic factors responsible for risk of breast and prostate cancer are largely unknown. Mutations in genes currently known to be associated with susceptibility only account for a small proportion of the familial aggregation of these cancers. I will be applying new genetic technology to population-based studies of cancer to identify new genetic and epigenetic markers of cancer risk. I will use this information to improve health care for families with prostate and breast cancer.
Defining The Role Of The PSA-related Kallikrein Serine Proteases In Hormone Dependent Cancer Progression
Funder
National Health and Medical Research Council
Funding Amount
$880,454.00
Summary
Kallikreins are a family of 15 proteins, related to the prostate cancer biomarker PSA, that have potential as biomarkers for hormone dependent cancers such as prostate and ovarian cancer. Prof Judith Clements and her team discovered that kallikreins induce resistance to chemotherapy in ovarian cancer and are found in prostate cancer bone disease. Her research will determine the underlying mechanisms of kallikrein action and their potential as new biomarkers or treatment targets for these disease ....Kallikreins are a family of 15 proteins, related to the prostate cancer biomarker PSA, that have potential as biomarkers for hormone dependent cancers such as prostate and ovarian cancer. Prof Judith Clements and her team discovered that kallikreins induce resistance to chemotherapy in ovarian cancer and are found in prostate cancer bone disease. Her research will determine the underlying mechanisms of kallikrein action and their potential as new biomarkers or treatment targets for these diseases.Read moreRead less
Professor Michael Parker from St Vincent’s Institute in Melbourne is one of Australia’s leading structural biologists. He will use his Fellowship to help establish a Cancer Structural Biology Centre to provide early stage drug discovery tools which will aid many of Australia’s leading cancer researchers to translate their basic discoveries into drugs. This work will utilise key major infrastructure investments including the Australian Synchrotron.
The overall goal of the program is to develop novel approaches to slow the progress or prevent neurodegeneration in patients with rare human genetic disorders. The second program is designed to develop novel therapeutics from snake venom proteins. These include proteins with anti-bleeding activity and those with application in wound healing. The third program involves the development of novel biomarkers for the early detection and prognosis in prostate cancer.
Elimination Of Zoonotic Schistosomiasis And Echinococcosis Through Integrated Morbidity Control
Funder
National Health and Medical Research Council
Funding Amount
$898,008.00
Summary
I am a parasitologist researching the biology, immunology and epidemiology of human parasitic worms, particularly the schistosome bloodflukes and the hydatid tapeworms, which cause bilharzia and hydatidosis, diseases of the world’s poorest people that cause both major suffering and economic loss. My goal is to develop new methods, including vaccination, to control and eventually eliminate these parasites.
Immunological Prevention Of Cysticercosis And Hydatid Disease
Funder
National Health and Medical Research Council
Funding Amount
$802,685.00
Summary
Professor Lightowlers’ has developed the world’s most effective vaccines against diseases caused by parasites. The vaccines prevent transmission of parasites from livestock animals to humans. During the next 5 years the vaccines will be produced on a large scale and evaluated in field trials. The products of this research program will make a major contribution to reducing the number of people suffering from parasitic cysts.
Therapeutic And Diagnostic Approaches For The Neurodegenerative Diseases
Funder
National Health and Medical Research Council
Funding Amount
$804,106.00
Summary
Diseases of the brain such as Alzheimer’s and Parkinson’s disease cause enormous socio-economic harm to Australia. They are a major cause of disability and the burden associated with mental illness is predicted to grow by almost 50% over the coming decade. Therefore there is an urgent need to develop new approaches to identify and treat these diseases. This Fellowship will be dedicated to creating new diagnostic methods and treatments for these diseases